Gujarat Themis Biosyn Ltd
₹ 387
1.04%
12 Jun
- close price
About
Incorporated in 1981, Gujarat Themis Biosyn
Ltd manufactures and sells finished Active Pharmaceutical Ingredients products by fermentation process[1]
Key Points
- Market Cap ₹ 4,220 Cr.
- Current Price ₹ 387
- High / Low ₹ 479 / 225
- Stock P/E 90.4
- Book Value ₹ 26.4
- Dividend Yield 0.17 %
- ROCE 17.9 %
- ROE 17.4 %
- Face Value ₹ 1.00
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 23.1%
Cons
- Stock is trading at 14.7 times its book value
- Company might be capitalizing the interest cost
- Debtor days have increased from 89.3 to 134 days.
- Promoter holding has decreased over last 3 years: -4.13%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 | 33 | 36 | 39 | 41 | 85 | 91 | 115 | 148 | 170 | 151 | 166 | |
| 25 | 27 | 30 | 33 | 34 | 53 | 50 | 57 | 75 | 91 | 81 | 90 | |
| Operating Profit | 7 | 6 | 6 | 6 | 7 | 32 | 40 | 58 | 74 | 79 | 70 | 76 |
| OPM % | 21% | 19% | 17% | 16% | 18% | 37% | 45% | 51% | 50% | 46% | 46% | 46% |
| -0 | 0 | 0 | 0 | 2 | 2 | 3 | 4 | 7 | 4 | 2 | 2 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 4 | 5 | 13 |
| Profit before tax | 5 | 5 | 5 | 5 | 8 | 31 | 41 | 59 | 77 | 79 | 66 | 62 |
| Tax % | 0% | 0% | 10% | 20% | 22% | 24% | 26% | 26% | 25% | 25% | 26% | 25% |
| 5 | 5 | 4 | 4 | 6 | 24 | 30 | 44 | 58 | 59 | 49 | 47 | |
| EPS in Rs | 0.42 | 0.42 | 0.40 | 0.36 | 0.59 | 2.17 | 2.77 | 4.00 | 5.32 | 5.43 | 4.48 | 4.28 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 10% | 0% | 37% | 14% | 12% | 15% | 16% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 13% |
| 3 Years: | 4% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 26% |
| 5 Years: | 9% |
| 3 Years: | -7% |
| TTM: | -4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 49% |
| 5 Years: | 59% |
| 3 Years: | 55% |
| 1 Year: | 16% |
| Return on Equity | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 29% |
| 3 Years: | 23% |
| Last Year: | 17% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 11 | 11 |
| Reserves | -8 | -3 | 1 | 5 | 11 | 35 | 63 | 96 | 142 | 194 | 237 | 277 |
| 6 | 3 | 4 | 1 | 6 | 8 | 5 | 1 | 0 | 3 | 30 | 162 | |
| 9 | 8 | 9 | 8 | 8 | 14 | 14 | 18 | 17 | 17 | 22 | 54 | |
| Total Liabilities | 15 | 15 | 21 | 20 | 33 | 64 | 88 | 122 | 166 | 221 | 301 | 503 |
| 10 | 9 | 11 | 11 | 15 | 17 | 19 | 19 | 33 | 38 | 41 | 289 | |
| CWIP | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 13 | 21 | 91 | 184 | 121 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5 | 5 | 11 | 10 | 17 | 47 | 67 | 90 | 113 | 92 | 76 | 93 | |
| Total Assets | 15 | 15 | 21 | 20 | 33 | 64 | 88 | 122 | 166 | 221 | 301 | 503 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 | 4 | 3 | 6 | 1 | 1 | 11 | 40 | 39 | 64 | 91 | 49 | |
| -0 | -1 | -3 | -1 | -6 | -3 | -2 | -30 | -20 | -55 | -112 | -172 | |
| -3 | -3 | -0 | -4 | 5 | 2 | -5 | -14 | -13 | -9 | 26 | 115 | |
| Net Cash Flow | -1 | -0 | 0 | 1 | 0 | -0 | 3 | -4 | 6 | 0 | 5 | -9 |
| Free Cash Flow | 2 | 3 | 0 | 5 | -5 | -3 | 7 | 26 | 16 | -10 | -25 | -124 |
| CFO/OP | 44% | 73% | 57% | 99% | 25% | 24% | 51% | 94% | 81% | 107% | 154% | 79% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 28 | 24 | 71 | 26 | 52 | 87 | 59 | 80 | 44 | 58 | 76 | 134 |
| Inventory Days | 78 | 194 | 144 | 255 | 201 | 33 | 75 | 263 | ||||
| Days Payable | 947 | 240 | 84 | 145 | 131 | 99 | 218 | 625 | ||||
| Cash Conversion Cycle | 28 | 24 | 71 | -844 | 52 | 41 | 119 | 189 | 114 | -7 | -67 | -228 |
| Working Capital Days | -76 | -70 | -42 | -43 | -58 | 42 | 80 | 155 | 91 | 50 | 46 | 8 |
| ROCE % | 121% | 81% | 55% | 42% | 45% | 84% | 67% | 67% | 61% | 45% | 27% | 18% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-term Maintenance of Peak Production Qualitative |
|
||||||||||
| Capacity Utilization % |
|||||||||||
| Total Physical Production Volume MT |
|||||||||||
| Installed Capacity (Rifamycin S and O) kg per annum |
|||||||||||
| Installed Fermentation Capacity KL |
|||||||||||
| Rifapentine API Capacity MT per month |
|||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Jun - Newspaper Publication of Postal Ballot Notice dated 6th June, 2026
- Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 8 Jun
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 6Th June, 2026
6 Jun - Board approved raising up to Rs. 1,000 crore via QIP and preferential issue, subject to approvals.
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 5 Jun
-
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
5 Jun - Postal ballot special resolutions passed on June 5, 2026, approving borrowing limits and loans/investments powers.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
May 2026TranscriptAI SummaryPPT
-
May 2026TranscriptAI SummaryPPT
-
Apr 2026TranscriptAI SummaryPPT
-
Feb 2026TranscriptAI SummaryPPT
-
Nov 2025TranscriptAI SummaryPPT
-
Aug 2025TranscriptAI SummaryPPT
-
May 2025TranscriptAI SummaryPPT
-
Feb 2025TranscriptAI SummaryPPT
-
Oct 2024TranscriptAI SummaryPPT
-
Jul 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023Transcript PPT REC
-
Aug 2023TranscriptAI SummaryPPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Jun 2022TranscriptAI SummaryPPT
-
Mar 2022TranscriptAI SummaryPPT
-
Nov 2021TranscriptPPT
-
Nov 2021Transcript PPT
-
Sep 2021TranscriptAI SummaryPPT
Business Overview[1][2]
Company manufactures pharmaceuticals and medicinal chemicals. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary). GTBL entered into Technical & Financial collaboration with Yuhan Corporation, South Korea, and became India’s first Company to start commercial production of the Anti-tuberculosis drug Rifampicin.